Terms: = Breast cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
441 results:
1. Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
Staropoli N; Scionti F; Farenza V; Falcone F; Luciano F; Renne M; Di Martino MT; Ciliberto D; Tedesco L; Crispino A; Labanca C; Cucè M; Esposito S; Agapito G; Cannataro M; Tassone P; Tagliaferri P; Arbitrio M
Biomed Pharmacother; 2024 May; 174():116478. PubMed ID: 38547766
[TBL] [Abstract] [Full Text] [Related]
2. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
Chen YR; Yu X; Xu LM; Mei J; Tian ML; Xu M; Jin QY; Ye LB; Yang SX
Xenobiotica; 2024 Jan; 54(1):38-44. PubMed ID: 38085693
[TBL] [Abstract] [Full Text] [Related]
3. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of the effect of cyp2d6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.
Saghafi F; Salehifar E; Ebrahimi P; Shiran MR; Zaboli E; Sohrevardi SM; Jamialahmadi T; Sahebnasagh A; Sahebkar A
J Pharm Biomed Anal; 2024 Jan; 238():115839. PubMed ID: 37976989
[TBL] [Abstract] [Full Text] [Related]
5.
Ramírez G; Vital M; Vergara C; Carusso F; Neffa F; Valle AD; Esperón P
Per Med; 2023 Nov; 20(6):477-483. PubMed ID: 37947089
[No Abstract] [Full Text] [Related]
6. Design, synthesis, and in-silico study of novel triarylethylene analogs with dual anti-estrogenic and serotonergic activity.
Mostafa T; Albeir M; Wober J; Abadi A; Salama I; Ahmed NS
Drug Dev Res; 2024 Feb; 85(1):e22127. PubMed ID: 37877739
[TBL] [Abstract] [Full Text] [Related]
7. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in breast cancer Patients with cyp2d6*10 Mutant Genotypes.
Li X; Li Z; Li L; Liu T; Qian C; Ren Y; Li Z; Chen K; Ji D; Zhang M; Wang J
Cancer Res Treat; 2024 Jan; 56(1):134-142. PubMed ID: 37591782
[TBL] [Abstract] [Full Text] [Related]
8. Cannabidiol's impact on drug-metabolization.
Stöllberger C; Finsterer J
Eur J Intern Med; 2023 Dec; 118():6-13. PubMed ID: 37541924
[TBL] [Abstract] [Full Text] [Related]
9. Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing.
Golubenko EO; Savelyeva MI; Sozaeva ZA; Korennaya VV; Poddubnaya IV; Valiev TT; Kondratenko SN; Ilyin MV
Drug Metab Pers Ther; 2023 Dec; 38(4):339-347. PubMed ID: 37466310
[TBL] [Abstract] [Full Text] [Related]
10. Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro.
Ishikawa R; Saito K; Misawa T; Demizu Y; Saito Y
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371582
[TBL] [Abstract] [Full Text] [Related]
11. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
[TBL] [Abstract] [Full Text] [Related]
12. Profiling of pharmacogenomic variants in
Alsulaiman A; Chu H; Al-Jumaan M; Alyahya M; Marzooq YA; Almulhim F; Vatte C; Alnimer A; Almuhanna A; Al-Ali A; AlDubayan SH
Pharmacogenomics; 2023 May; 24(7):411-423. PubMed ID: 37222147
[No Abstract] [Full Text] [Related]
13. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.
Souwer ETD; Sanchez-Spitman A; Moes DJAR; Gelderblom H; Swen JJ; Portielje JEA; Guchelaar HJ; van Gelder T
Breast Cancer Res Treat; 2023 Jun; 199(3):471-478. PubMed ID: 37067610
[TBL] [Abstract] [Full Text] [Related]
14. Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co-Medications on Tamoxifen Metabolism in Black South African Women with breast cancer.
Chiwambutsa SM; Ayeni O; Kapungu N; Kanji C; Thelingwani R; Chen WC; Mokone DH; O'Neil DS; Neugut AI; Jacobson JS; Ruff P; Cubasch H; Joffe M; Masimirembwa C
Clin Pharmacol Ther; 2023 Jul; 114(1):127-136. PubMed ID: 37042388
[TBL] [Abstract] [Full Text] [Related]
15. Early increase in tamoxifen dose in cyp2d6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.
Blancas I; Linares-Rodríguez M; Martínez de Dueñas E; Herrero-Vicent C; Molero-Mir MD; Garrido JM; Rodríguez-Serrano F
Breast; 2023 Jun; 69():342-348. PubMed ID: 37011481
[TBL] [Abstract] [Full Text] [Related]
16. Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records.
Thorén L; Margolin S; Eliasson E; Bergh J; Lindh JD
Breast Cancer Res Treat; 2023 Apr; 198(3):499-508. PubMed ID: 36856936
[TBL] [Abstract] [Full Text] [Related]
17. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous cyp2d6 activity scale.
Agema BC; Buijs SM; Sassen SDT; Mürdter TE; Schwab M; Koch BCP; Jager A; van Schaik RHN; Mathijssen RHJ; Koolen SLW
Biomed Pharmacother; 2023 Apr; 160():114369. PubMed ID: 36753957
[TBL] [Abstract] [Full Text] [Related]
18. Cross-Ancestry Genome-Wide Association Study Defines the Extended cyp2d6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.
Khor CC; Winter S; Sutiman N; Mürdter TE; Chen S; Lim JSL; Li Z; Li J; Sim KS; Ganchev B; Eccles D; Eccles B; Tapper W; Zgheib NK; Tfayli A; Ng RCH; Yap YS; Lim E; Wong M; Wong NS; Ang PCS; Dent R; Tremmel R; Klein K; Schaeffeler E; Zhou Y; Lauschke VM; Eichelbaum M; Schwab M; Brauch HB; Chowbay B; Schroth W
Clin Pharmacol Ther; 2023 Mar; 113(3):712-723. PubMed ID: 36629403
[TBL] [Abstract] [Full Text] [Related]
19. Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study.
El Desoky ES; Taha AF; Mousa HS; Ibrahim A; Saleh MA; Abdelrady MA; Hareedy MS
J Oncol Pharm Pract; 2023 Oct; 29(7):1673-1686. PubMed ID: 36567618
[TBL] [Abstract] [Full Text] [Related]
20. Genetic Polymorphisms of Cytochromes P450 in Finno-Permic Populations of Russia.
Dzhaubermezov M; Ekomasova N; Mustafin R; Gabidullina L; Galimova Y; Nurgalieva A; Valova Y; Prokofyeva D; Khusnutdinova E
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553620
[TBL] [Abstract] [Full Text] [Related]
[Next]